AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36335393 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement of calcifications with SAD (Group D + SAD)
Number of subjects: 69
Study 32307089 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic HFpEF patients
Number of subjects: 0
Study 615803878 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy with gemcitabine, dexamethasone, cisplatin (GDP) or dexamethasone, cytarabine, cisplatin (DHAP) followed by autologous stem cell transplantation (ASCT)
Number of subjects: 177
Study 33891570 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure on three acupuncture points (LI4, SP6, ST36) for three minutes twice daily for four weeks
Number of subjects: 31
Study 33891570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study 33618735 — intervention group
Group type: EXPERIMENTAL
Intervention: Senyuman Indah Milik Semua Programme (SIMSP)
Number of subjects: 28
Study 33618735 — intervention group
Group type: COMPARATOR
Intervention: Existing preschool oral healthcare programme (POHP)
Number of subjects: 28
Study 34959080 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic liver disease measured by the Dallas Steatosis Index (DSI) in ACCORD (median DSI 1.0, IQR 0.2-1.8)
Number of subjects: 5859
Study 34959080 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported chronic liver disease in SPRINT
Number of subjects: 5859
Study 34136057 — intervention group
Group type: EXPERIMENTAL
Intervention: Play therapy
Number of subjects: 72
Study 34136057 — intervention group
Group type: EXPERIMENTAL
Intervention: Hugo's point massage
Number of subjects: 72
Study 34136057 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 33308257 — intervention group
Group type: EXPERIMENTAL
Intervention: TB treatment adherence intervention (educational outreach, point-of-care reminder tool, peer support network)
Number of subjects: 798
Study 33308257 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 798
Study 35971596 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9977 100 mg once daily for 14 days, up-titrated to 200 mg for another 14 days
Number of subjects: 68
Study 35971596 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone 25 mg once daily for 14 days, up-titrated to 50 mg for another 14 days
Number of subjects: 68
Study 34886680 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg once daily
Number of subjects: 15076
Study 34886680 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg once daily
Number of subjects: 15076
Study 32272243 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Oral Suspension (BOS) 2.0 mg twice daily for 12 weeks
Number of subjects: 93
Study 32272243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 35692186 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (dose = 13‐49 mg)
Number of subjects: 85
Study 34836199 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized infant formula
Number of subjects: 0
Study 34836199 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater velocities of weight gain during early infancy
Number of subjects: 0
Study 34836199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower access to snacks as toddlers
Number of subjects: 0
Study 34836199 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy and added sugar intake
Number of subjects: 0
Study 33291249 — intervention group
Group type: EXPERIMENTAL
Intervention: Nominal group technique (NGT) sessions
Number of subjects: 33
Study 35704345 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban monotherapy
Number of subjects: 2215
Study 35704345 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with rivaroxaban and antiplatelet therapy
Number of subjects: 2215
Study 33279874 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab (15 mg/kg every 21 days)
Number of subjects: 152
Study 33279874 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib monotherapy (150 mg once daily)
Number of subjects: 152
Study 35369996 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual nurse-led education session on HF self-management during hospitalization and three telephone calls after discharge
Number of subjects: 122
Study 35369996 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 122
Study 33903059 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of discrimination based on age, sex, and race or ethnicity.
Number of subjects: 96110
Study 33903059 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of harassment related to race or ethnicity.
Number of subjects: 96110
Study 33903059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intersectionality analysis of discrimination and harassment experiences.
Number of subjects: 96110
Study 33903059 — intervention group
Group type: EXPERIMENTAL
Intervention: Harassment experiences from customers or patients.
Number of subjects: 96110
Study 33903059 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with reporting discrimination and harassment.
Number of subjects: 96110
Study 32171084 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time computer-aided system (ENDOANGEL)
Number of subjects: 0
Study 36054477 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative NSAIDs (administered from 24 hours pre-surgery to day 7 post-surgery)
Number of subjects: 204
Study 36054477 — intervention group
Group type: COMPARATOR
Intervention: Postoperative NSAIDs (administered from 12 hours post-surgery to day 7 post-surgery)
Number of subjects: 204
Study 33021047 — intervention group
Group type: EXPERIMENTAL
Intervention: Live lecture
Number of subjects: 94
Study 33021047 — intervention group
Group type: EXPERIMENTAL
Intervention: Video recorded lecture
Number of subjects: 94
Study 33021047 — intervention group
Group type: COMPARATOR
Intervention: Audio recorded lecture
Number of subjects: 94
Study 35710394 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care day patient approach
Number of subjects: 386
Study 35710394 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment as usual
Number of subjects: 386
Study 35710394 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Stepped care day patient approach and Inpatient treatment as usual)
Number of subjects: 386
Study 32469080 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus-preserving surgery (UPS)
Number of subjects: 185
Study 32469080 — intervention group
Group type: COMPARATOR
Intervention: Non-Uterus-preserving surgery (non-UPS)
Number of subjects: 185
Study 33721385 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling radiofrequency (MRF)
Number of subjects: 21
Study 33721385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional Er:YAG laser 2940 nm
Number of subjects: 21
Study 33721385 — intervention group
Group type: COMPARATOR
Intervention: Both MRF and Er:YAG laser
Number of subjects: 21
Study 32816177 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEPINCREMENTAL
Number of subjects: 60
Study 32816177 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEPDECREMENTAL
Number of subjects: 60
Study 33160946 — intervention group
Group type: EXPERIMENTAL
Intervention: Myval transcatheter heart valve (THV) series
Number of subjects: 768
Study 33160946 — intervention group
Group type: COMPARATOR
Intervention: Contemporary transcatheter heart valves (SAPIEN THV and Evolut THV series)
Number of subjects: 768
Study 33223005 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg.kg‐1 flurbiprofen axetil (Group C)
Number of subjects: 96
Study 33223005 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 flurbiprofen axetil (Group D)
Number of subjects: 96
Study 33223005 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of Intralipid (Group A, control group)
Number of subjects: 96
Study 33223005 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg.kg‐1 flurbiprofen axetil (Group B)
Number of subjects: 96
Study 36346795 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE labels on intervention items
Number of subjects: 19000
Study 36346795 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE labels on non-intervention items
Number of subjects: 19000
Study 36346795 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE labels on total energy purchased
Number of subjects: 19000
Study 32141787 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 400 U injection in J-PURE (upper limb)
Number of subjects: 22
Study 32141787 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 400 U injection in J-PLUS (lower limb)
Number of subjects: 22
Study 35229691 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma added to conventional therapy
Number of subjects: 0
Study 35229691 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (saline) control
Number of subjects: 0
Study 32241351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied every 4 weeks for 12 weeks
Number of subjects: 22
Study 32241351 — intervention group
Group type: COMPARATOR
Intervention: Control (sham application)
Number of subjects: 22
Study 32241351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 22
Study 35849650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 193
Study 35849650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 32621535 — intervention group
Group type: EXPERIMENTAL
Intervention: Deauville score (DS) 1 (n=34)
Number of subjects: 189
Study 32621535 — intervention group
Group type: EXPERIMENTAL
Intervention: Deauville score (DS) 2 (n=39)
Number of subjects: 189
Study 32621535 — intervention group
Group type: EXPERIMENTAL
Intervention: Deauville score (DS) 3 (n=46)
Number of subjects: 189
Study 32621535 — intervention group
Group type: EXPERIMENTAL
Intervention: Deauville score (DS) 4 (n=56)
Number of subjects: 189
Study 32621535 — intervention group
Group type: EXPERIMENTAL
Intervention: Deauville score (DS) 5 (n=14)
Number of subjects: 189
Study 32621535 — intervention group
Group type: EXPERIMENTAL
Intervention: ∆SUVmax ≥66% (n=168)
Number of subjects: 189
Study 32621535 — intervention group
Group type: EXPERIMENTAL
Intervention: ∆SUVmax <66% (n=21)
Number of subjects: 189
Study 32621535 — intervention group
Group type: EXPERIMENTAL
Intervention: Deauville score (DS) 1-5
Number of subjects: 189
Study 32621535 — intervention group
Group type: EXPERIMENTAL
Intervention: ∆SUVmax ≥66%
Number of subjects: 189
Study 32621535 — intervention group
Group type: EXPERIMENTAL
Intervention: ∆SUVmax <66%
Number of subjects: 189
Study 34036828 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic visual oral examinations for screening
Number of subjects: 0
Study 34036828 — intervention group
Group type: COMPARATOR
Intervention: Opportunistic screening in dental practices
Number of subjects: 0
Study 34036828 — intervention group
Group type: COMPARATOR
Intervention: Use of primary health care workers for oral cancer screening
Number of subjects: 0
Study 32470370 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg Diclofenac Potassium (DFK)
Number of subjects: 70
Study 32470370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 32470370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 33877274 — intervention group
Group type: EXPERIMENTAL
Intervention: Poloxamer 188
Number of subjects: 388
Study 33877274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 33866827 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-HRRP penalty phase (2013-2017)
Number of subjects: 6669313
Study 33866827 — intervention group
Group type: COMPARATOR
Intervention: Pre-HRRP penalty phase (2010-2012)
Number of subjects: 6669313
Study 33866827 — intervention group
Group type: EXPERIMENTAL
Intervention: 2010-2017 trend analysis
Number of subjects: 6669313
Study 35853436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 441
Study 35853436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 33738466 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary rhinoplasty
Number of subjects: 134
Study 33738466 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision rhinoplasty
Number of subjects: 134
Study 33738466 — intervention group
Group type: COMPARATOR
Intervention: Comparison of revision rhinoplasty to primary rhinoplasty
Number of subjects: 134
Study 32551724 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogical Exposure Therapy (DET)
Number of subjects: 110
Study 32551724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 110
Study 32551724 — intervention group
Group type: COMPARATOR
Intervention: Both therapies (DET and CPT)
Number of subjects: 110
Study 36089507 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet based on plant proteins
Number of subjects: 90
Study 36089507 — intervention group
Group type: COMPARATOR
Intervention: DASH diet based on animal proteins
Number of subjects: 90
Study 36170543 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials delivered with 'take‐home and cook‐with‐friends' meal kits
Number of subjects: 186
Study 36170543 — intervention group
Group type: COMPARATOR
Intervention: Meal kits only (control group)
Number of subjects: 186
Study 33126095 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-industry counter-advertising (CA)
Number of subjects: 1316
Study 33126095 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-product counter-advertising (CA)
Number of subjects: 1316
Study 33126095 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative health effects counter-advertising (CA)
Number of subjects: 1316
Study 33126095 — intervention group
Group type: COMPARATOR
Intervention: Control (neutral advertisement)
Number of subjects: 1316
Study 33926539 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) followed by chemotherapy
Number of subjects: 228
Study 33926539 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 228
Study 33284852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative games
Number of subjects: 285
Study 34460897 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week outpatient physical therapy program with progressive resistance training (PRT)
Number of subjects: 100
Study 34460897 — intervention group
Group type: COMPARATOR
Intervention: 6-week outpatient physical therapy program with progressive resistance training (PRT)
Number of subjects: 100
Study 34460897 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 12-week and 6-week groups
Number of subjects: 100
Study 33452496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 16
Study 33452496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Number of subjects: 16
Study 33452496 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study 32532789 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg once every 2 weeks until disease progression or unacceptable toxicity
Number of subjects: 270
Study 36113907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 52
Study 36113907 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 52
Study 33630677 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (CT)
Number of subjects: 55
Study 33630677 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 55
Study 32131366 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A received a sachet containing 5 g CPs, 3.6 g calcium lactate (equivalent to 500 mg of elemental calcium) and 400 IU vitamin D3
Number of subjects: 51
Study 32131366 — intervention group
Group type: COMPARATOR
Intervention: Group B received a chewable tablet containing 1.25 g calcium carbonate (equivalent to 500 mg of elemental calcium) and 400 IU vitamin D3 daily
Number of subjects: 51
Study 33496967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative dexmedetomidine
Number of subjects: 0
Study 33496967 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32379687 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D for 12 weeks
Number of subjects: 0
Study 32379687 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 0
Study 36347107 — intervention group
Group type: EXPERIMENTAL
Intervention: GOT + IOT
Number of subjects: 102
Study 36347107 — intervention group
Group type: COMPARATOR
Intervention: GOT alone
Number of subjects: 102
Study 34286863 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care education programme (video-assisted teaching, tailored teaching at discharge, guide on self-care, telephonic calls and text messages for 6 months)
Number of subjects: 160
Study 34286863 — intervention group
Group type: COMPARATOR
Intervention: Standard care plus self-care guide
Number of subjects: 160
Study 35213433 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green group
Number of subjects: 64
Study 35213433 — intervention group
Group type: COMPARATOR
Intervention: Nonindocyanine green group
Number of subjects: 64
Study 35213433 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study 36400573 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom model
Number of subjects: 42
Study 36400573 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture method (Control)
Number of subjects: 42
Study 34337893 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia (NX; room air; FIO2 0.21)
Number of subjects: 28
Study 34337893 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia (HX; FIO2 0.148)
Number of subjects: 28
Study 32764898 — intervention group
Group type: EXPERIMENTAL
Intervention: FNB (femoral nerve block) with 15 mL of 0.5% ropivacaine
Number of subjects: 46
Study 32764898 — intervention group
Group type: COMPARATOR
Intervention: FICB (fascia iliaca compartment block) with 40 mL of 0.5% ropivacaine
Number of subjects: 46
Study 32814922 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispatcher-assisted cardiopulmonary resuscitation instructions
Number of subjects: 21
Study 36385193 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (3200 IU/d)
Number of subjects: 36
Study 36385193 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol (HyD, 20 mcg/d)
Number of subjects: 36
Study 36385193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 34448725 — intervention group
Group type: EXPERIMENTAL
Intervention: App intervention
Number of subjects: 54
Study 34448725 — intervention group
Group type: EXPERIMENTAL
Intervention: App usage
Number of subjects: 54
Study 32934291 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel insecticide‐based intervention
Number of subjects: 0
Study 32934291 — intervention group
Group type: COMPARATOR
Intervention: Deltamethrin exposure
Number of subjects: 0
Study 32934291 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptome analysis
Number of subjects: 0
Study 32934291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyp6P3 expression
Number of subjects: 0
Study 34742935 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS Kind Mind Program
Number of subjects: 0
Study 33433351 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of perindopril tert-butylamine tablets (4 mg)
Number of subjects: 64
Study 34263280 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of daidzein with 10 g soy protein
Number of subjects: 165
Study 34263280 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of genistein with 10 g soy protein
Number of subjects: 165
Study 34263280 — intervention group
Group type: COMPARATOR
Intervention: 0 mg of daidzein and genistein with 10 g soy protein (placebo group)
Number of subjects: 165
Study 34949544 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided magnesium bioresorbable scaffold (MBRS) implantation
Number of subjects: 75
Study 34949544 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided magnesium bioresorbable scaffold (MBRS) implantation
Number of subjects: 75
Study 34604139 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Number of subjects: 70
Study 34604139 — intervention group
Group type: COMPARATOR
Intervention: Orotracheal intubation
Number of subjects: 70
Study 35247994 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise intervention (supervised and group-based exercise training, primarily intermediate to high intensity interval training, three times per week for 6 weeks)
Number of subjects: 70
Study 35247994 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise intervention
Number of subjects: 70
Study 35247994 — intervention group
Group type: COMPARATOR
Intervention: Standard oncological treatments (checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance)
Number of subjects: 70
Study 32610246 — intervention group
Group type: COMPARATOR
Intervention: Efficient ICUs
Number of subjects: 13635
Study 32610246 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance of ventilator-associated pneumonia
Number of subjects: 13635
Study 32610246 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilization of central venous catheters
Number of subjects: 13635
Study 34951124 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Hyrax (HHG)
Number of subjects: 42
Study 34951124 — intervention group
Group type: COMPARATOR
Intervention: Hyrax (HG)
Number of subjects: 42
Study 32342662 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPA intervention with tailored text messages
Number of subjects: 60
Study 32342662 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 36379661 — intervention group
Group type: EXPERIMENTAL
Intervention: My Life After Stroke (MLAS) programme
Number of subjects: 420
Study 36379661 — intervention group
Group type: COMPARATOR
Intervention: Declined MLAS
Number of subjects: 420
Study 32666354 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate monohydrate extended release tablets
Number of subjects: 0
Study 32666354 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro dissolution tests using USP apparatus 1 at 75 rpm with HCl pH 1.2, acetate buffer solution pH 4.5, or phosphate buffer solution pH 6.8
Number of subjects: 0